Developer docs
API playgroundTry for free, no card

Search company profiles

Xbrane Bioscience

Full company profile

uuid0006568

Namestring
Xbrane Bioscience
Websiteurl
xbrane.com
Company typeenum
Private
Founded yearint
2008
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSolna, Sweden
HQ citystring
Solna
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
biosimilar development, biopharmaceutical products, protein expression technology, monoclonal antibody biosimilars, biopharmaceutical R&D
Industry3 codes
PRIMARYHLAAAHAA
Monoclonal Antibody (mAb) Biosimilars
SECONDARYHLAAAHAG
Oncology Biosimilars
SECONDARYHLAIAFAA
Monoclonal Antibody (mAb) Biosimilars
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biosimilar Pharmaceuticals
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Xbrane Bioscience is a biopharmaceutical company that develops biosimilars, principally an Opdivo (nivolumab) biosimilar candidate intended for regulatory approval and commercialization. Its offering is underpinned by proprietary bacterial protein expression technology used to manufacture biosimilar proteins for oncology indications.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Xbrane Bioscience was a biopharmaceutical company focused on developing biosimilars. The company developed an Opdivo (nivolumab) biosimilar candidate, which was undergoing clinical trials as of 2025. Xbrane's R&D organization in Sweden was acquired by Alvotech as part of Alvotech's expansion of its global biosimilars footprint.

Product and service1 record
1Opdivo Biosimilar
CategoryBiosimilars
Description

A biosimilar candidate targeting Opdivo (nivolumab), being developed for potential regulatory approval and commercialization as a more cost-effective alternative to the originator oncology biologic.

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Alvotech acquired Xbrane's R&D organization in Sweden, expanding its global footprint and capabilities in the biosimilars space. This acquisition represents a significant strategic transaction where Xbrane's R&D capabilities were transferred to Alvotech.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

India-based biosimilar developer with a broad mAb biosimilar pipeline including oncology assets. Directly comparable business model focused on developing and commercializing biosimilars for global markets.

2Sandoz (Novartis)
TypeBroad incumbent
Description

Global leader in generics and biosimilars, spun out from Novartis, with a substantial biosimilar portfolio including oncology mAbs. Comparable as a broad incumbent in the biosimilars market rather than a niche specialist.

TypeDirect peer
Description

European biosimilar developer with a pipeline of mAb biosimilars including oncology candidates. Comparable as a focused biosimilar company with operations overlapping Xbrane's European base.

TypeDirect peer
Description

Global biosimilar developer with a portfolio of monoclonal antibody biosimilars and the acquirer of Xbrane's R&D organization. Directly comparable as a pure-play biosimilar company targeting the same class of complex biologics.

TypeBroad incumbent
Description

Global pharmaceutical company formed from Mylan and Upjohn with a defined biosimilars franchise including oncology assets. Comparable as a broad incumbent commercializing biosimilars across multiple regions.

TypeDirect peer
Description

South Korean biopharmaceutical company and pioneer in mAb biosimilars (Remsima/Inflectra). Comparable as a vertically integrated biosimilar developer with strong commercial reach in oncology and immunology biosimilars.

TypeBroad incumbent
Description

Global biopharmaceutical company with a biosimilars portfolio built through the Hospira acquisition. Comparable as a broad incumbent participating in the biosimilars market alongside a much larger innovative drug portfolio.

TypeDirect peer
Description

U.S.-based biopharmaceutical company commercializing biosimilars and immuno-oncology products. Directly comparable in business model and target therapeutic areas, with active biosimilar pipeline assets.

TypeDirect peer
Description

Biosimilar-focused joint venture between Samsung Biologics and Biogen, developing multiple mAb biosimilars including oncology candidates. Closely comparable in scale, technology focus, and pipeline composition.

TypeBroad incumbent
Description

Major biopharmaceutical company with an established biosimilars division (e.g., Amjevita, Mvasi). Comparable as a large incumbent developing and commercializing biosimilars alongside a broader innovative biologics portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Xbrane Bioscience

Biosimilar Pharmaceuticalsxbrane.com

Xbrane Bioscience firmographics

Firmographics
Name
Xbrane Bioscience
Website
https://xbrane.com
Company type
Private
Founded year
2008
Operating status
Acquired
Headcount range
51–100 employees
Ownership category
akta.pro rank

Xbrane Bioscience industry classification

Industry
Product category
Biosimilar Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAHAA
Monoclonal Antibody (mAb) Biosimilars
SECONDARYHLAAAHAG
Oncology Biosimilars
SECONDARYHLAIAFAA
Monoclonal Antibody (mAb) Biosimilars

Keywords

  • Biosimilar development
  • Biopharmaceutical products
  • Protein expression technology
  • Monoclonal antibody biosimilars
  • Biopharmaceutical R&D

Where Xbrane Bioscience is headquartered

Location

Headquarters

HQ city
Solna
HQ country
Sweden
HQ region
Europe

Markets served

Xbrane Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Xbrane Bioscience product offering

Product offering

Core offering

Xbrane Bioscience is a biopharmaceutical company that develops biosimilars, principally an Opdivo (nivolumab) biosimilar candidate intended for regulatory approval and commercialization. Its offering is underpinned by proprietary bacterial protein expression technology used to manufacture biosimilar proteins for oncology indications.

Product overview

Xbrane Bioscience was a biopharmaceutical company focused on developing biosimilars. The company developed an Opdivo (nivolumab) biosimilar candidate, which was undergoing clinical trials as of 2025. Xbrane's R&D organization in Sweden was acquired by Alvotech as part of Alvotech's expansion of its global biosimilars footprint.

Differentiator

Problem solved

Functional benefit

Products and services

  • Opdivo Biosimilar A biosimilar candidate targeting Opdivo (nivolumab), being developed for potential regulatory approval and commercialization as a more cost-effective alternative to the originator oncology biologic.

Companies that use Xbrane Bioscience

Customer profile

Ideal customer profiles1 record

Xbrane Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Xbrane Bioscience partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • AlvotechcoreStrategic or Co-development PartnerAlvotech acquired Xbrane's R&D organization in Sweden, expanding its global footprint and capabilities in the biosimilars space. This acquisition represents a significant strategic transaction where Xbrane's R&D capabilities were transferred to Alvotech.

Recent moves5 records

Expansion highlights4 records

Xbrane Bioscience competitors and assessment

Company assessment

Direct peers

  • Biocon Biologics: India-based biosimilar developer with a broad mAb biosimilar pipeline including oncology assets. Directly comparable business model focused on developing and commercializing biosimilars for global markets.
  • Polpharma Biologics: European biosimilar developer with a pipeline of mAb biosimilars including oncology candidates. Comparable as a focused biosimilar company with operations overlapping Xbrane's European base.
  • Alvotech: Global biosimilar developer with a portfolio of monoclonal antibody biosimilars and the acquirer of Xbrane's R&D organization. Directly comparable as a pure-play biosimilar company targeting the same class of complex biologics.
  • Celltrion: South Korean biopharmaceutical company and pioneer in mAb biosimilars (Remsima/Inflectra). Comparable as a vertically integrated biosimilar developer with strong commercial reach in oncology and immunology biosimilars.
  • Coherus Biosciences: U.S.-based biopharmaceutical company commercializing biosimilars and immuno-oncology products. Directly comparable in business model and target therapeutic areas, with active biosimilar pipeline assets.
  • Samsung Bioepis: Biosimilar-focused joint venture between Samsung Biologics and Biogen, developing multiple mAb biosimilars including oncology candidates. Closely comparable in scale, technology focus, and pipeline composition.

Broad incumbents

  • Sandoz (Novartis): Global leader in generics and biosimilars, spun out from Novartis, with a substantial biosimilar portfolio including oncology mAbs. Comparable as a broad incumbent in the biosimilars market rather than a niche specialist.
  • Viatris: Global pharmaceutical company formed from Mylan and Upjohn with a defined biosimilars franchise including oncology assets. Comparable as a broad incumbent commercializing biosimilars across multiple regions.
  • Pfizer: Global biopharmaceutical company with a biosimilars portfolio built through the Hospira acquisition. Comparable as a broad incumbent participating in the biosimilars market alongside a much larger innovative drug portfolio.
  • Amgen: Major biopharmaceutical company with an established biosimilars division (e.g., Amjevita, Mvasi). Comparable as a large incumbent developing and commercializing biosimilars alongside a broader innovative biologics portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Xbrane Bioscience social profiles

Digital presence

Xbrane Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Xbrane Bioscience leadership team

Management profile

Number of profiles

Profiles2 records

Xbrane Bioscience funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Xbrane Bioscience M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xbrane Bioscience

What does Xbrane Bioscience do?

Xbrane Bioscience is a biopharmaceutical company that develops biosimilars, principally an Opdivo (nivolumab) biosimilar candidate intended for regulatory approval and commercialization. Its offering is underpinned by proprietary bacterial protein expression technology used to manufacture biosimilar proteins for oncology indications.

Is Xbrane Bioscience a public or private company?

Xbrane Bioscience is a private company. It is classified as public and is currently acquired.

When was Xbrane Bioscience founded?

Xbrane Bioscience was founded in 2008. It employs 51 to 100 people.

Where is Xbrane Bioscience based?

Xbrane Bioscience is headquartered in Solna, Sweden, in the Europe region.

Who are Xbrane Bioscience's main competitors?

Direct peers on record are Biocon Biologics, Polpharma Biologics, Alvotech, Celltrion, Coherus Biosciences and Samsung Bioepis. Broad incumbents are Sandoz (Novartis), Viatris, Pfizer and Amgen.

Does Xbrane Bioscience have an API?

No public API is recorded for Xbrane Bioscience.

What industry is Xbrane Bioscience in?

Xbrane Bioscience's product category is Biosimilar Pharmaceuticals. Its primary akta.pro industry code is HLAAAHAA, Monoclonal Antibody (mAb) Biosimilars, with a secondary code of HLAAAHAG, Oncology Biosimilars. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewXbrane receives GMP authorization from the Swedish Medical Products Agency, strengthening commercial supply capabilitiesXbrane Biopharma received GMP authorization from the Swedish Medical Products Agency to import and release EU medicinal products from third countries. The authorization strengthens Ximluci's supply chain and supports future biosimilar candidates like Xdarzane.Drug Store NewsFDA approves Xbrane Biopharma's Lucentis biosimilarThe FDA approved Xbrane Biopharma's biosimilar Lucamzi (ranibizumab-blrz) for treating neovascular age-related macular degeneration and other eye conditions. The company plans to launch the product in 2027 with partners.TradingViewXbrane Biopharma Q3 2026 Earnings Call Is LiveXbrane Biopharma's Q3 2026 earnings call is live, with executives set to discuss financial results and answer analyst questions. Management commentary on future demand, margins, or capital spending may move markets.Dagens industriXbrane Biopharma minskar förlustenXbrane Biopharma reported an EBITDA loss of 6.6 million Swedish kronor for the third quarter of 2026. The company, a biosimilar developer, posted a loss of 20.7 million kronor for the quarter. The article is behind a paywall, so no further details are available.MarketScreenerXbrane Biopharma Wins US FDA Approval for Lucentis BiosimilarThe US FDA approved Xbrane Biopharma's biosimilar Lucamzi on October 27, 2026. The approval follows the company's earlier filing for the Lucentis biosimilar.YahooXbrane Biopharma AB (STU:7XB0) Q2 2026 Earnings Call Highlights: Strategic Moves and Financial ...Xbrane Biopharma AB resumed shipments of finished goods to Stada, generating a profit sharing of 127 million Swedish crowns in Q2 2026. The company has resubmitted its BLA to the FDA for its biosimilar product XinLucine, with a decision expected in October 2026, while also entering a co-development agreement with Join Biologics for a Darzalex biosimilar candidate. However, the company reported a low gross margin of 5% due to revised profit sharing and inventory adjustments, with negative operating cash flow of minus 4.8 million Swedish crowns, indicating ongoing financial pressure.MarketScreenerXbrane receives FDA PDUFA date for LucamziXbrane received an FDA PDUFA date for Lucamzi after resubmitting its application in April, following a Complete Response Letter issued last October. The product, approved and launched in Europe as Ximluci since 2023, is planned for U.S. marketing under the name Lucamzi.MarketScreenerXbrane Biopharma swings to operating lossXbrane Biopharma reported a Q1 2026 operating loss of SEK 10.5 million and a net loss of SEK 13.1 million, with net sales falling 81.4% to SEK 17.3 million. The company said it can finance operations for the foreseeable future based on its manufacturing plan and sales to STADA.GlobeNewswireTrastuzumab Biosimilars Market Analysis Report 2026: $24.48 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe trastuzumab biosimilars market is projected to grow from $6.9 billion in 2025 to $8.86 billion in 2026, with a CAGR of 28.5%. It is expected to reach $24.48 billion by 2030, driven by rising cancer incidence and patent exclusivity loss. North America led 2025, while the Middle East is anticipated to grow fastest.MarketScreenerXbrane resubmits BLA for ranibizumab biosimilar in the USXbrane resubmitted its BLA for a ranibizumab biosimilar in the US after completing corrective actions following a Complete Response Letter in October 2024. The new review period is expected to last about six months, with the goal of securing US approval and a more cost-effective treatment alternative.